Biopharmaceutical company Cerenis Therapeutics is set to acquire Lypro Biosciences assets, a portfolio of drug delivery nanotechnology.
The acquisition represents the company’s strategic objective of developing new multiple targeted drug delivery nanotechnologies associated with HDL therapy.
Cerenis Therapeutics CEO Jean-Louis Dasseux said: “Building on the strong foundation of our lead HDL product, CER-001, this acquisition opens another therapeutic area characterised by a significant unmet medical need, while allowing us to leverage our leading HDL therapy capabilities to drive the development of this potentially revolutionary technology.
“We look forward to initiating the Phase I trial of NanoDisk and advancing other HDL-based assets, including CER-209 for NAFLD and NASH, in order to create value for patients, the medical community and other key stakeholders of CERENIS Therapeutics.”
Lypro Biosciences’ NanoDisk technology will be combined with Cerenis’ HDL technology to build the first HDL particle delivery platform for the oncology market.
“Building on the strong foundation of our lead HDL product, CER-001, this acquisition opens another therapeutic area characterised by a significant unmet medical need.”
Lypro Biosciences founder and board member Robert Ryan said: “The product candidates that Lypro has developed and associated with CERENIS’ proprietary HDL technology, could have a tremendous impact on the field of oncology, and we believe that CERENIS Therapeutics is the optimal company to lead future advancements of this groundbreaking technology.”
Cerenis will acquire Lypro Biosciences assets, including patent rights and in-depth pre-clinical data showing the efficacy of lipid structures in encapsulating and delivering active drugs to tissues.
Lypro’s NanoDisk technology is based on self-assembling, targetable, nanometer-scale bioparticles, incorporating active drugs into NanoDisk.
The stable and water-soluble NanoDisk, when combined with the Cerenis HDL, CER-001, targets a specific human cell HDL receptor, SR-B1.
The SR-B1 and other HDL receptors (ABCA1) serve as a potential gateway for the delivery of therapeutic agents.
10 November 2017